7 aad (Cytek Biosciences)
Cytek Biosciences is a verified supplier 
Cytek Biosciences manufactures this product 
96
Structured Review
Cytek Biosciences
7 aad
7 Aad, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/7+aad/7-AAD/pmc13011060-429-10-12
Average 96 stars, based on 1 article reviews
7 Aad, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/7+aad/7-AAD/pmc13011060-429-10-12
Average 96 stars, based on 1 article reviews
7 aad - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Staining:Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. Article Snippet: SIYspecific CD8+ T cells were stained with SIY tetramer (T-Select H-2Kb Negative (SIY) Tetramer, MBL, 2.5% v/v) and incubated for 20 min at room temperature. .. After washing and diluting in Brilliant Stain Buffer (BD Biosciences), the cells were stained with the following fluorochromeconjugated antibodies for 20 min at room temperature: • CD45 BUV395 (30-F11, BD Horizon), 0.2% • TCRβ BUV737 (H57-597, BD Horizon), 1% • CD8 AF647 (KT15, MBL), 0.625% • CD4 AF700 (RM4-5, BioLegend), 0.5% AR TI CL E IN P RE SS • CD49a PE-Cy7 (HMa1, BioLegend), 1% • CD49b PerCP/Cy5.5 (HMa1, BioLegend), 1% • PD-1 BV605 (29F.1A12, BioLegend), 1% • MHC-II (I-A/I-E) FITC (M5/114.15.2; BioLegend), 1% • CD62L BV711 (MEL-14, BioLegend), 0.5% • CD44 BV785 (IM7, BioLegend), 0.5% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: For staining, 1 × 105 PBMCs were incubated with human IgG (FUJIFILM) as an Fc blocker (1% v/v) for 30 min at 4 °C, followed by adding the antibody cocktail without washing. .. The following fluorochrome-conjugated antibodies were used: TCRα/β BUV737 (IP26, BD OptiBuild), 1% CD8 BUV395 (RPA-T8, BD Horizon), 0.125% CD4 APC-Cy7 (RPA-T4, TONBO Biosciences), 0.5% CD49a PE-Cy7 (TS2/7, BioLegend), 2% CD49b FITC (P1E6-C5, BioLegend), 2% CD45RA vF450 (HI100, TONBO Biosciences), 0.5% HLA-DR PE/Dazzle 594 (L243, BioLegend), 2% CD38 BV711 (HIT2, BioLegend), 2% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: .. Thawed cryopreserved cells were washed using CTL Anti-Aggregate Wash (Cellular Technology Ltd.) and stained with Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: SIY-specific CD8+ T cells were stained with SIY tetramer (T-Select H-2Kb Negative (SIY) Tetramer, MBL, 2.5% v/v) and incubated for 20 min at room temperature. .. After washing and diluting in Brilliant Stain Buffer (BD Biosciences), the cells were stained with the following fluorochrome-conjugated antibodies for 20 min at room temperature: CD45 BUV395 (30-F11, BD Horizon), 0.2% TCRβ BUV737 (H57-597, BD Horizon), 1% CD8 AF647 (KT15, MBL), 0.625% CD4 AF700 (RM4-5, BioLegend), 0.5% CD49a PE-Cy7 (HMa1, BioLegend), 1% CD49b PerCP/Cy5.5 (HMa1, BioLegend), 1% PD-1 BV605 (29 F.1A12, BioLegend), 1% MHC-II (I-A/I-E) FITC (M5/114.15.2; BioLegend), 1% CD62L BV711 (MEL-14, BioLegend), 0.5% CD44 BV785 (IM7, BioLegend), 0.5% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. Article Snippet: For staining, 1 × 105 PBMCs were incubated with human IgG (FUJIFILM) as an Fc blocker (1% v/v) for 30 min at 4 °C, followed by adding the antibody cocktail without washing. .. The following fluorochrome-conjugated antibodies were used: • TCRα/β BUV737 (IP26, BD OptiBuild), 1% AR TI CL E IN P RE SS • CD8 BUV395 (RPA-T8, BD Horizon), 0.125% • CD4 APC-Cy7 (RPA-T4, TONBO Biosciences), 0.5% • CD49a PE-Cy7 (TS2/7, BioLegend), 2% • CD49b FITC (P1E6-C5, BioLegend), 2% • CD45RA vF450 (HI100, TONBO Biosciences), 0.5% • HLA-DR PE/Dazzle 594 (L243, BioLegend), 2% • CD38 BV711 (HIT2, BioLegend), 2% Immunopeptidomics:Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. Article Snippet: SIYspecific CD8+ T cells were stained with SIY tetramer (T-Select H-2Kb Negative (SIY) Tetramer, MBL, 2.5% v/v) and incubated for 20 min at room temperature. .. After washing and diluting in Brilliant Stain Buffer (BD Biosciences), the cells were stained with the following fluorochromeconjugated antibodies for 20 min at room temperature: • CD45 BUV395 (30-F11, BD Horizon), 0.2% • TCRβ BUV737 (H57-597, BD Horizon), 1% • CD8 AF647 (KT15, MBL), 0.625% • CD4 AF700 (RM4-5, BioLegend), 0.5% AR TI CL E IN P RE SS • CD49a PE-Cy7 (HMa1, BioLegend), 1% • CD49b PerCP/Cy5.5 (HMa1, BioLegend), 1% • PD-1 BV605 (29F.1A12, BioLegend), 1% • MHC-II (I-A/I-E) FITC (M5/114.15.2; BioLegend), 1% • CD62L BV711 (MEL-14, BioLegend), 0.5% • CD44 BV785 (IM7, BioLegend), 0.5% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: SIY-specific CD8+ T cells were stained with SIY tetramer (T-Select H-2Kb Negative (SIY) Tetramer, MBL, 2.5% v/v) and incubated for 20 min at room temperature. .. After washing and diluting in Brilliant Stain Buffer (BD Biosciences), the cells were stained with the following fluorochrome-conjugated antibodies for 20 min at room temperature: CD45 BUV395 (30-F11, BD Horizon), 0.2% TCRβ BUV737 (H57-597, BD Horizon), 1% CD8 AF647 (KT15, MBL), 0.625% CD4 AF700 (RM4-5, BioLegend), 0.5% CD49a PE-Cy7 (HMa1, BioLegend), 1% CD49b PerCP/Cy5.5 (HMa1, BioLegend), 1% PD-1 BV605 (29 F.1A12, BioLegend), 1% MHC-II (I-A/I-E) FITC (M5/114.15.2; BioLegend), 1% CD62L BV711 (MEL-14, BioLegend), 0.5% CD44 BV785 (IM7, BioLegend), 0.5% Flow Cytometry:Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. Article Snippet: SIYspecific CD8+ T cells were stained with SIY tetramer (T-Select H-2Kb Negative (SIY) Tetramer, MBL, 2.5% v/v) and incubated for 20 min at room temperature. .. After washing and diluting in Brilliant Stain Buffer (BD Biosciences), the cells were stained with the following fluorochromeconjugated antibodies for 20 min at room temperature: • CD45 BUV395 (30-F11, BD Horizon), 0.2% • TCRβ BUV737 (H57-597, BD Horizon), 1% • CD8 AF647 (KT15, MBL), 0.625% • CD4 AF700 (RM4-5, BioLegend), 0.5% AR TI CL E IN P RE SS • CD49a PE-Cy7 (HMa1, BioLegend), 1% • CD49b PerCP/Cy5.5 (HMa1, BioLegend), 1% • PD-1 BV605 (29F.1A12, BioLegend), 1% • MHC-II (I-A/I-E) FITC (M5/114.15.2; BioLegend), 1% • CD62L BV711 (MEL-14, BioLegend), 0.5% • CD44 BV785 (IM7, BioLegend), 0.5% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: For staining, 1 × 105 PBMCs were incubated with human IgG (FUJIFILM) as an Fc blocker (1% v/v) for 30 min at 4 °C, followed by adding the antibody cocktail without washing. .. The following fluorochrome-conjugated antibodies were used: TCRα/β BUV737 (IP26, BD OptiBuild), 1% CD8 BUV395 (RPA-T8, BD Horizon), 0.125% CD4 APC-Cy7 (RPA-T4, TONBO Biosciences), 0.5% CD49a PE-Cy7 (TS2/7, BioLegend), 2% CD49b FITC (P1E6-C5, BioLegend), 2% CD45RA vF450 (HI100, TONBO Biosciences), 0.5% HLA-DR PE/Dazzle 594 (L243, BioLegend), 2% CD38 BV711 (HIT2, BioLegend), 2% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: SIY-specific CD8+ T cells were stained with SIY tetramer (T-Select H-2Kb Negative (SIY) Tetramer, MBL, 2.5% v/v) and incubated for 20 min at room temperature. .. After washing and diluting in Brilliant Stain Buffer (BD Biosciences), the cells were stained with the following fluorochrome-conjugated antibodies for 20 min at room temperature: CD45 BUV395 (30-F11, BD Horizon), 0.2% TCRβ BUV737 (H57-597, BD Horizon), 1% CD8 AF647 (KT15, MBL), 0.625% CD4 AF700 (RM4-5, BioLegend), 0.5% CD49a PE-Cy7 (HMa1, BioLegend), 1% CD49b PerCP/Cy5.5 (HMa1, BioLegend), 1% PD-1 BV605 (29 F.1A12, BioLegend), 1% MHC-II (I-A/I-E) FITC (M5/114.15.2; BioLegend), 1% CD62L BV711 (MEL-14, BioLegend), 0.5% CD44 BV785 (IM7, BioLegend), 0.5% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. Article Snippet: For staining, 1 × 105 PBMCs were incubated with human IgG (FUJIFILM) as an Fc blocker (1% v/v) for 30 min at 4 °C, followed by adding the antibody cocktail without washing. .. The following fluorochrome-conjugated antibodies were used: • TCRα/β BUV737 (IP26, BD OptiBuild), 1% AR TI CL E IN P RE SS • CD8 BUV395 (RPA-T8, BD Horizon), 0.125% • CD4 APC-Cy7 (RPA-T4, TONBO Biosciences), 0.5% • CD49a PE-Cy7 (TS2/7, BioLegend), 2% • CD49b FITC (P1E6-C5, BioLegend), 2% • CD45RA vF450 (HI100, TONBO Biosciences), 0.5% • HLA-DR PE/Dazzle 594 (L243, BioLegend), 2% • CD38 BV711 (HIT2, BioLegend), 2% Recombinant:Article Title: Nanoplastics target lung monocytes, disrupting immune dynamics. Article Snippet: • Systemically exposed nanoplastics preferentially accumulate in the lungs.. • Nonclassical monocytes and CD206interstitial macrophages sequester nanoplastics in the lungs.. • Nanoplastics delay the conversion of monocytes to macrophages in the lungs. Red Blood Cell Lysis:Article Title: Nanoplastics target lung monocytes, disrupting immune dynamics. Article Snippet: • Systemically exposed nanoplastics preferentially accumulate in the lungs.. • Nonclassical monocytes and CD206interstitial macrophages sequester nanoplastics in the lungs.. • Nanoplastics delay the conversion of monocytes to macrophages in the lungs. Liposomes:Article Title: Nanoplastics target lung monocytes, disrupting immune dynamics. Article Snippet: • Systemically exposed nanoplastics preferentially accumulate in the lungs.. • Nonclassical monocytes and CD206interstitial macrophages sequester nanoplastics in the lungs.. • Nanoplastics delay the conversion of monocytes to macrophages in the lungs. Control:Article Title: Nanoplastics target lung monocytes, disrupting immune dynamics. Article Snippet: • Systemically exposed nanoplastics preferentially accumulate in the lungs.. • Nonclassical monocytes and CD206interstitial macrophages sequester nanoplastics in the lungs.. • Nanoplastics delay the conversion of monocytes to macrophages in the lungs. Electron Microscopy:Article Title: Nanoplastics target lung monocytes, disrupting immune dynamics. Article Snippet: • Systemically exposed nanoplastics preferentially accumulate in the lungs.. • Nonclassical monocytes and CD206interstitial macrophages sequester nanoplastics in the lungs.. • Nanoplastics delay the conversion of monocytes to macrophages in the lungs. Recombinase Polymerase Amplification:Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer Article Snippet: For staining, 1 × 105 PBMCs were incubated with human IgG (FUJIFILM) as an Fc blocker (1% v/v) for 30 min at 4 °C, followed by adding the antibody cocktail without washing. .. The following fluorochrome-conjugated antibodies were used: TCRα/β BUV737 (IP26, BD OptiBuild), 1% CD8 BUV395 (RPA-T8, BD Horizon), 0.125% CD4 APC-Cy7 (RPA-T4, TONBO Biosciences), 0.5% CD49a PE-Cy7 (TS2/7, BioLegend), 2% CD49b FITC (P1E6-C5, BioLegend), 2% CD45RA vF450 (HI100, TONBO Biosciences), 0.5% HLA-DR PE/Dazzle 594 (L243, BioLegend), 2% CD38 BV711 (HIT2, BioLegend), 2% Article Title: Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. Article Snippet: For staining, 1 × 105 PBMCs were incubated with human IgG (FUJIFILM) as an Fc blocker (1% v/v) for 30 min at 4 °C, followed by adding the antibody cocktail without washing. .. The following fluorochrome-conjugated antibodies were used: • TCRα/β BUV737 (IP26, BD OptiBuild), 1% AR TI CL E IN P RE SS • CD8 BUV395 (RPA-T8, BD Horizon), 0.125% • CD4 APC-Cy7 (RPA-T4, TONBO Biosciences), 0.5% • CD49a PE-Cy7 (TS2/7, BioLegend), 2% • CD49b FITC (P1E6-C5, BioLegend), 2% • CD45RA vF450 (HI100, TONBO Biosciences), 0.5% • HLA-DR PE/Dazzle 594 (L243, BioLegend), 2% • CD38 BV711 (HIT2, BioLegend), 2% Double Staining:Article Title: Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia–reperfusion lung injury and pneumonia Article Snippet: .. Apoptosis was detected using double staining with Annexin V-APC and |